Track Emergent BioSolutions Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Emergent BioSolutions Inc. EBS Open Emergent BioSolutions Inc. in new tab

7.94 USD
P/E
8.74
EPS
-0.19
P/B
0.81
ROE
-1.60
Beta
2.33
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc.

🧾 Earnings Recap – Q1 2026

Emergent shares rose 3.8% after the quarter, reflecting market approval of better-than-expected revenue and adjusted EBITDA results, driven by solid demand in medical countermeasures and continued naloxone leadership.

  • Q1 revenue of $156 million exceeded the high end of guidance and internal expectations.
  • Adjusted EBITDA reached $36 million, with a 23% margin, driven by operational efficiency and cost controls.
  • Medical Countermeasures (MCM) segment performed well, supported by global demand and a $140 million multiproduct agreement with Canada.
  • Naloxone franchise maintains market share leadership; recent product launches (carrying case, multipack) showing early positive traction.
  • Continued balance sheet improvement with $110 million debt repayment in 2025 and ongoing share repurchases totaling $34 million since 2025 start.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
P/E8.74
EPS-0.19
Book Value10.10
Price to Book0.81
Debt/Equity111.76
% Insiders3.864%
Growth
Revenue Growth-0.30%
Earnings Growth-0.94%
Estimates
Forward P/E2.75
Forward EPS2.99

DCF Valuation

Tweak assumptions to recompute fair value for Emergent BioSolutions Inc. (EBS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Emergent BioSolutions Inc. Logo Emergent BioSolutions Inc. Analysis (EBS)

United States Health Care Official Website Stock

Is Emergent BioSolutions Inc. a good investment? Emergent BioSolutions Inc. (EBS) is currently trading at 7.94 USD.

In terms of valuation, the stock trades at a P/E ratio of 8.74. This relatively low multiple may signal that Emergent BioSolutions Inc. is undervalued compared to historical market norms.

Earnings Schedule: Emergent BioSolutions Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is 2.99.

Investor FAQ

Does Emergent BioSolutions Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Emergent BioSolutions Inc.?

Emergent BioSolutions Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -0.19.

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Exchange Ticker
NYQ (United States) EBS
HAM (Germany) EBS.HM
LSE (United Kingdom) 0IGA.L
FRA (Germany) ER4.F
STU (Germany) ER4.SG

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion